Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
Open Access
- 14 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (1), 131-138
- https://doi.org/10.1038/bjc.2011.199
Abstract
Cholangiocarcinoma (CC) is a highly malignant carcinoma. We attempted to clarify the prognostic significance of c-Met overexpression and its association with clinicopathological factors in patients with CC. One hundred and eleven patients with intrahepatic CC (IHCC) and 136 patients with extrahepatic CC (EHCC) who had undergone curative surgery were divided immunohistologically into c-Methigh and c-Metlow groups. Clinicopathological factors and outcomes were compared between the groups. c-Met and epidermal growth factor receptor (EGFR) expression was also examined in 10 CC cell lines. The positivity of c-Met was 45.0% in IHCC and 68.4% in EHCC; c-Methigh expression was demonstrated in 11.7% of IHCC and 16.2% of EHCC. c-Methigh expression was significantly correlated with the 5-year survival rate for CC overall (P=0.0046) and for IHCC (P=0.0013), histopathological classification in EHCC, and for EGFR overexpression in both IHCC and EHCC. Coexpression and coactivation of c-Met and EGFR were also observed in CC cell lines. Multivariate analysis revealed that c-Methigh expression was an independent predictor of poor overall and disease-free survival in patients with IHCC. c-Met overexpression is associated with EGFR expression and is a poor prognostic factor in CC.Keywords
This publication has 44 references indexed in Scilit:
- Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatmentCancer Science, 2009
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinomaBritish Journal of Cancer, 2009
- Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in CancerClinical Cancer Research, 2008
- Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatmentHepatology, 2008
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 2008
- The Met tyrosine kinase receptor in development and cancerCancer and Metastasis Reviews, 2008
- Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth FactorMolecular Cancer Research, 2008
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBritish Journal of Cancer, 2007
- c-met mRNA overexpression in human hepatocellular carcinomaJournal of Hepatology, 1994
- The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.The Journal of cell biology, 1993